Voyager Therapeutics

$8.67
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.17 (+2.00%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell VYGR and other stocks, options, and ETFs commission-free!

About VYGR

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA. The listed name for VYGR is Voyager Therapeutics, Inc. Common Stock.

CEO

G. Andre Turenne

Employees

185

Headquarters

Cambridge, Massachusetts

Founded

2013

Market Cap

324.83M

Price-Earnings Ratio

8.17

Dividend Yield

—

Average Volume

471.03K

High Today

$8.80

Low Today

$8.53

Open Price

$8.75

Volume

583.66K

52 Week High

$14.62

52 Week Low

$6.26

Collections

Analyst Ratings

46%

of 13 ratings

Buy

46%

Hold

54%

Sell

VYGR Earnings

-$0.81

$0.22

$1.24

$2.27

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 3, After Hours